BioMarin Pharmaceutical (BMRN) Earnings Date, Estimates & Call Transcripts → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free BMRN Stock Alerts $80.91 -1.26 (-1.53%) (As of 04/26/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateJul. 29EstimatedActual EPS (Feb. 22) $0.49 Beat By $0.05 Consensus EPS (Feb. 22) $0.45 Read Call TranscriptListen to CallLatest SEC 10-Q Filing Get BioMarin Pharmaceutical Earnings AlertsEnter your email address below to receive the latest news and earnings results for BMRN and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueBMRN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BMRN Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. BioMarin Pharmaceutical Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20242$0.36$0.36$0.36 Q2 20242$0.42$0.61$0.52 Q3 20242$0.44$0.71$0.58 Q4 20243$0.37$0.95$0.62 FY 20249$1.59$2.63$2.07 Q1 20251$0.57$0.57$0.57 Q2 20251$0.60$0.60$0.60 Q3 20251$0.58$0.58$0.58 Q4 20251$0.66$0.66$0.66 FY 20254$2.41$2.41 $2.41BMRN Earnings Date and InformationBioMarin Pharmaceutical last posted its quarterly earnings results on February 22nd, 2024. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.05. The firm had revenue of $646.21 million for the quarter, compared to analyst estimates of $639.53 million. Its quarterly revenue was up 20.2% on a year-over-year basis. BioMarin Pharmaceutical has generated $1.07 earnings per share over the last year ($1.07 diluted earnings per share) and currently has a price-to-earnings ratio of 75.6. Earnings for BioMarin Pharmaceutical are expected to grow by 48.65% in the coming year, from $1.85 to $2.75 per share. BioMarin Pharmaceutical has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, July 29th, 2024 based off prior year's report dates.Read More BioMarin Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 7/29/2024Estimated)------- 2/22/2024Q4 2023$0.4450$0.49+$0.0450$0.41$639.53 million$646.21 million 11/1/2023Q3 2023$0.28$0.26($0.02)$0.31$603.51 million$581.33 million7/31/2023Q2 2023$0.24$0.34+$0.10$0.39$591.46 million$595.28 million4/26/2023Q1 2023$0.24$0.39+$0.15$0.51$572.53 million$596.42 million2/27/2023Q4 2022$0.12$0.11($0.01)$0.22$533.88 million$537.54 million10/26/2022Q3 2022$0.12$0.16+$0.04$0.36$516.03 million$505.30 million Get the Latest News and Ratings for BMRN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 8/3/2022Q2 2022$0.20$0.33+$0.13$0.51$514.18 million$533.80 million 4/27/2022Q1 2022$0.15$0.31+$0.16($0.01)$505.11 million$519.36 million 2/23/2022Q4 2021($0.22)($0.21)+$0.01($0.10)$442.38 million$449.81 million 10/26/2021Q3 2021($0.25)($0.20)+$0.05$0.14$435.29 million$408.74 million 7/27/2021Q2 2021($0.11)$0.07+$0.18$0.39$448.84 million$501.69 million 4/28/2021Q1 2021$0.07$0.09+$0.02$0.49$445.44 million$486.03 million BioMarin Pharmaceutical Earnings - Frequently Asked Questions When is BioMarin Pharmaceutical's earnings date? BioMarin Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, July 29th, 2024 based off last year's report dates. Learn more on BMRN's earnings history. Did BioMarin Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, BioMarin Pharmaceutical (NASDAQ:BMRN) reported $0.49 earnings per share (EPS) to beat the analysts' consensus estimate of $0.45 by $0.05. Learn more on analysts' earnings estimate vs. BMRN's actual earnings. How can I listen to BioMarin Pharmaceutical's earnings conference call? The conference call for BioMarin Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call How can I read BioMarin Pharmaceutical's conference call transcript? The conference call transcript for BioMarin Pharmaceutical's latest earnings report can be read online. Read Transcript How can I view BioMarin Pharmaceutical's earnings report? BioMarin Pharmaceutical's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does BioMarin Pharmaceutical generate each year? BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded annual revenue of $2.42 billion. How much profit does BioMarin Pharmaceutical generate each year? BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded net income of $167.65 million. BMRN has generated $1.07 earnings per share over the last four quarters. What is BioMarin Pharmaceutical's price-to-earnings ratio? BioMarin Pharmaceutical (NASDAQ:BMRN) has a trailing price-to-earnings ratio of 75.62 and a forward price-to-earnings ratio of 43.74. The price/earnings-to-growth ratio is 1.68. What is BioMarin Pharmaceutical's EPS forecast for next year? BioMarin Pharmaceutical's earnings are expected to grow from $1.85 per share to $2.75 per share in the next year, which is a 48.65% increase. More Earnings Resources from MarketBeat Related Companies: ALNY Earnings Date UTHR Earnings Date IONS Earnings Date MDGL Earnings Date GMAB Earnings Date TEVA Earnings Date VTRS Earnings Date BGNE Earnings Date KRTX Earnings Date RDY Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:BMRN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsMan Who Predicted 2008: “This Will be Worse.”AltimetryYou Won't Believe Who Bezos is Working With to Fight Alzheimer'sBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
